The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation.

Summary

According to the abstract, the cohort covered consecutive adult first bilateral lung transplants performed between 1999 and 2017. Biopsies from the first post-transplant year were paired with FEV1; the first spirometrically stable minimal (A1) acute cellular rejection episode that was not treated with augmented immunosuppression was compared with a time-matched stable episode without rejection. Cox models showed no significant difference in the risk of CLAD or death. The abstract opens by stating that acute cellular rejection (ACR) is a significant risk factor for CLAD, and concludes that, in clinically stable patients, an untreated first A1 episode was not significantly associated with increased risk in this study. The authors include Tereza Martinu, Stephen Juvet and Shaf Keshavjee. This record gives no advice on management.

Details

doi

10.1111/ajt.15561

pmid

31397939

authors

Levy L, Huszti E, Tikkanen J, Ghany R, Klement W, Ahmed M, Husain S, Fiset PO, Hwang D, Keshavjee S, Singer LG, Juvet S, Martinu T

journal

American Journal of Transplantation

year

2020

volume

20

issue

1

pages

241-249

Sources and links

• Publisher record via DOI (primary)
• PubMed 31397939

Related

Links from this record

• coauthor: Tereza Martinu
• coauthor: Stephen Juvet
• affiliation named in PubMed record (Toronto Lung Transplant Program): Toronto Lung Transplant Program (University Health Network)

Linked from (derived)

• biopsy grading: Transbronchial biopsy: histology and transcript-based classifiers
• supports and qualifies: Acute cellular rejection
• author: Lianne Singer
• author: Shaf Keshavjee

Known gaps in this record

• full text not read (abstract only)
• funding statement and grant numbers
• full author affiliations (only the PubMed affiliation text was checked for named centres)